These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25265656)

  • 1. [The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis].
    Avdeev AS; Novikov AA; Aleksandrova EN; Panasiuk EIu; Nasonov EL
    Klin Med (Mosk); 2014; 92(1):28-34. PubMed ID: 25265656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The immunologic predictors of effect of anti-B-cell therapy under rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Nasonov EL
    Klin Lab Diagn; 2014 Mar; (3):48-52. PubMed ID: 25080789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
    Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
    Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: a prospective observational cohort study.
    Su J; Hu W; Ding Y; Zhang P; Li T; Liu S; Xing L
    Arthritis Res Ther; 2024 Jul; 26(1):130. PubMed ID: 38997725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt.
    Romão VC; Santos MJ; Polido-Pereira J; Duarte C; Nero P; Miguel C; Costa JA; Bernardes M; Pimentel-Santos FM; Barcelos F; Costa L; Melo Gomes JA; Pereira da Silva JA; Cunha Branco J; Canas da Silva J; Pereira da Silva JA; Fonseca JE; Canhão H
    Biomed Res Int; 2015; 2015():279890. PubMed ID: 26000286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
    Levi M; Grange S; Frey N
    J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
    Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis.
    Kasama T; Isojima S; Umemura M; Tsukamoto H; Tokunaga T; Furuya H; Yanai R; Takahashi R; Nakamura M; Inagaki K
    Rheumatol Int; 2014 Mar; 34(3):429-33. PubMed ID: 23670804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
    Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
    PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
    Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
    Hitchon CA; Alex P; Erdile LB; Frank MB; Dozmorov I; Tang Y; Wong K; Centola M; El-Gabalawy HS
    J Rheumatol; 2004 Dec; 31(12):2336-46. PubMed ID: 15570632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].
    Zhu HL; DU Q; Chen WL; Zuo XX; Li QZ; Liu SJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):716-722. PubMed ID: 31420628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer.
    Kumari N; Agrawal U; Mishra AK; Kumar A; Vasudeva P; Mohanty NK; Saxena S
    Tumour Biol; 2017 Apr; 39(4):1010428317697552. PubMed ID: 28378639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
    Snir A; Kessel A; Haj T; Rosner I; Slobodin G; Toubi E
    Clin Exp Rheumatol; 2011; 29(4):697-700. PubMed ID: 21813064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy.
    Wright HL; Bucknall RC; Moots RJ; Edwards SW
    Rheumatology (Oxford); 2012 Mar; 51(3):451-9. PubMed ID: 22179732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.